Lourdes Felix
LIXTE BIOTECHNOLOGY HOLDINGSAbout Lourdes Felix
Hispanic entrepreneur with 30+ years in management, corporate finance, capital markets, and public accounting; currently CEO, CFO, and Director of BioCorRx Inc. (OTCQB: BICX). Appointed as an independent director of LIXTE effective September 1, 2025; age 57; holds a B.S. in Accounting (Business Management concentration) from University of Phoenix . At LIXTE, she serves as Audit Committee Chair and member of the Compensation Committee; the Board has affirmatively determined she is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BioCorRx Inc. | CEO, CFO, Director | 2012–present | Secured >$40M in equity/non-dilutive funding; launched UnCraveRx (2019); negotiated acquisition of LUCEMYRA (2025); extensive SEC/SOX compliance leadership |
| BioCorRx Pharmaceuticals Inc. | Founding Member, President | Not disclosed | Oversees commercialization, development, regulatory recruitment, strategic planning, M&A |
| Public accounting and private sector | Various finance roles | Not disclosed | Deep GAAP, SEC, SOX, internal controls expertise |
External Roles
| Company | Role | Tenure | Committees/Position |
|---|---|---|---|
| Avalon GloboCare Corporation (NASDAQ: ALBT) | Director; Compensation Committee Chair | 2023–present | Compensation Committee Chair |
| La Rosa Holdings Corp. (NASDAQ: LRHC) | Director; Audit Committee Chair | 2024–present | Audit Committee Chair |
| BioCorRx Inc. (OTCQB: BICX) | CEO, CFO, Director | 2012–present | Executive management; Board member |
Board Governance
- Committee assignments: Audit Committee (Felix, Sawyer, Primus) with Felix as Chair; Board determined each Audit Committee member is independent and financially literate; Felix designated “audit committee financial expert” under Item 407(d)(5) .
- Compensation Committee: Felix, Primus, Sawyer; Sawyer serves as Chair; Board determined all members are independent; one meeting in 2024 .
- Independence: Board affirmatively determined Lourdes Felix is independent under Nasdaq rules .
- Attendance: Board held nine meetings in 2024; each director attended ≥75% of Board and applicable committee meetings (historical disclosure) .
- Board leadership: CEO chairs Board; risk oversight shared by the full Board and committees; Audit Committee charter covers approval of related-party transactions .
- Governance documents and charters available on company website; no formal policy requiring attendance at annual meeting of stockholders .
Fixed Compensation
| Component | Amount (Annual) | Notes | Applicability to Felix (Sep 2025) |
|---|---|---|---|
| Base director retainer (cash, payable quarterly) | $20,000 | Directors may elect cash or immediate-vesting options each quarter (5-year term; strike at grant; Black-Scholes conversion) | Yes (director) |
| Audit Committee Chair fee | $10,000 | Additional annual cash; quarterly election for options permitted | Yes (Audit Chair) |
| Audit Committee member fee | $5,000 | Additional annual cash; quarterly election for options permitted | Not applicable if Chair only (policy does not clarify stacking; Board custom not disclosed) |
| Other committee Chair fee | $5,000 | Additional annual cash; quarterly election for options permitted | No (not Chair of Compensation) |
| Other committee member fee | $2,500 | Additional annual cash; quarterly election for options permitted | Yes (Compensation Committee member) |
Note: In 2024, the Board temporarily paid director cash compensation via immediately vested options (in lieu of cash) to preserve cash; this program covered Q2–Q4 2024, and the Board indicated the approach could be extended beyond 2024 .
Performance Compensation
| Award Type | Shares/Units | Vesting | Strike Price Basis | Grant Date | Status for Felix |
|---|---|---|---|---|---|
| New director option grant | 25,000 options | 50% at grant; remainder vests 12.5% quarterly thereafter over ~2 years (5-year term) | Closing market price on grant date | On appointment (policy; specific grant not disclosed) | Not disclosed in filings; beneficial ownership table shows 0 as of 9/30/2025 |
| Annual outside director option grant | 10,000 options | 12.5% quarterly vesting over 2 years (5-year term) | Closing market price on grant date | Last business day of June annually | 2025 grant not disclosed for Felix |
Historical context: In prior years, outside directors received annual 10,000 options; in 2024, immediate-vesting quarterly option grants were used in lieu of cash compensation to conserve cash .
Other Directorships & Interlocks
| Company | Role | Potential Interlock/Conflict Consideration |
|---|---|---|
| Avalon GloboCare Corporation (NASDAQ: ALBT) | Director; Compensation Committee Chair | No disclosed transactions with LIXTE; governance role outside LIXTE . |
| La Rosa Holdings Corp. (NASDAQ: LRHC) | Director; Audit Committee Chair | No disclosed transactions with LIXTE; governance role outside LIXTE . |
| BioCorRx Inc. (OTCQB: BICX) | CEO, CFO, Director | Different therapeutic focus (addiction treatment); no disclosed related-party transactions with LIXTE . |
Expertise & Qualifications
- Strategic financial leadership across biotech; SEC reporting, compliance, risk management, internal controls; GAAP/SOX expertise .
- Audit committee financial expert designation at LIXTE; Spanish fluency and community engagement .
- Capital markets execution (>$40M funding), commercialization initiatives (UnCraveRx), and recent M&A (LUCEMYRA) .
Equity Ownership
| Holder | Beneficial Ownership (Shares) | Percent of Class | As-of Date |
|---|---|---|---|
| Lourdes Felix | 0 | 0.0% | September 30, 2025 |
Shares outstanding were 5,704,200 as of September 30, 2025 (excludes convertible preferred and pre-funded warrants); table reflects options/warrants/convertibles exercisable within 60 days included for each person—Felix reported 0 .
Governance Assessment
- Strengths: Independent director with audit committee financial expert status; chairs LIXTE’s Audit Committee and contributes to Compensation Committee; Board confirms committee independence; charters and Code of Ethics publicly available .
- Alignment considerations: Beneficial ownership shows 0 shares as of 9/30/2025; while director policy supports equity grants, specific grants to Felix are not disclosed—investors may seek evidence of equity alignment via reported grants or open-market purchases .
- Time-commitment risk: Concurrent roles as CEO/CFO at BioCorRx and board/committee leadership positions at two other public companies may raise overboarding/time allocation questions; no attendance data specific to Felix yet (appointed Sep 2025); Board historically reports ≥75% attendance by directors .
- Related-party/conflict review: No related-party transactions disclosed involving Felix; Audit Committee charter explicitly covers related-party transaction approvals .
- Compensation structure: Current policy allows quarterly election of cash vs immediately-vesting options and standard option grants for new/annual director compensation; 2025 proxy notes ongoing review of director compensation policy—investors should monitor for changes in mix or quantum .
RED FLAGS to monitor:
- Zero beneficial ownership as of the latest table (seek confirmation of equity grant/election post-appointment) .
- Multi-board and executive commitments across BioCorRx, ALBT, LRHC—monitor attendance and engagement at LIXTE in upcoming proxies .
Appendix: Committee Activity (Historical)
| Committee | Meetings in 2024 | Notes |
|---|---|---|
| Audit Committee | 3 | New composition (Felix as Chair) set after Sep 1, 2025; 2024 meetings reflect prior membership . |
| Compensation Committee | 1 | New composition includes Felix (member); 2024 frequency reflects prior Board . |